Page 1304 - Hematology_ Basic Principles and Practice ( PDFDrive )

1150 Part VII Hematologic Malignancies

REFERENCES 7. Thiele J, Kvasnicka HM, Werden C, et al: Idiopathic primary osteo-
myelofibrosis: a clinico-pathological study on 208 patients with special
1. Swerdlow SH, Campo E, Harris NL, et al: WHO classification of tumours emphasis on evolution of disease features, differentiation from essential
of haematopoietic and lymphoid tissues, ed 4, 2008. thrombocythemia and variables of prognostic impact. Leuk Lymphoma
2. Tefferi A: Novel mutations and their functional and clinical relevance in 22:303, 1996.
myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH 8. Lundberg P, Karow A, Nienhold R, et al: Clonal evolution and clinical
and IKZF1. Leukemia 24:1128, 2010. correlates of somatic mutations in myeloproliferative neoplasms. Blood
3. Schmitt A, Jouault H, Guichard J, et al: Pathologic interaction between 123(14):2220, 2014.
megakaryocytes and polymorphonuclear leukocytes in myelofibrosis. 9. Cervantes F, Dupriez B, Pereira A, et al: New prognostic scoring system
Blood 96:1342, 2000. for primary myelofibrosis based on a study of the International Working
4. James C, Ugo V, Le Couédic JP, et al: A unique clonal JAK2 mutation Group for Myelofibrosis Research and Treatment. Blood 113:2895, 2009.
leading to constitutive signalling causes polycythaemia vera. Nature 10. Tefferi A: How I treat myelofibrosis. Blood 117:3494, 2011.
434:1144, 2005. 11. Kiladjian JJ, Mesa RA, Hoffman R: The renaissance of interferon therapy
5. Pardanani AD, Levine RL, Lasho T, et al: MPL515 mutations in myelo- for the treatment of myeloid malignancies. Blood 117:4706, 2011.
proliferative and other myeloid disorders: a study of 1182 patients. Blood 12. Verstovsek S, Mesa RA, Gotlib J, et al: A double-blind, placebo-controlled
108:3472, 2006. trial of ruxolitinib for myelofibrosis. N Engl J Med 366:799, 2012.
6. Nangalia J, Massie CE, Baxter EJ, et al: Somatic CALR mutations in 13. Harrison C, Kiladjian JJ, Al-Ali HK, et al: JAK inhibition with rux-
myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med olitinib versus best available therapy for myelofibrosis. N Engl J Med
369(25):2391, 2013. 366:787, 2012.